Trial Profile
A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Efficacy and Safety of 3 Different Dose Levels (2.5, 7.5 and 20 mg) of MM-093 in Patients With Active Rheumatoid Arthritis on Stable Doses of Methotrexate
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs Recombinant alpha fetoprotein (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merrimack Pharmaceuticals
- 12 Oct 2005 New trial record.